Gylvin Lykke Hinsch - 02 Jun 2026 Form 4/A - Amendment Insider Report for ProQR Therapeutics N.V. (PRQR)

Reporting relationship: Director
Issuer ticker: PRQR
Reported as of: 02 Jun 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 30 Jun 2026, 16:02:38 UTC
Original report date: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Pieter Erik de Ridders, Attorney-in-Fact

Key filing fact

Gylvin Lykke Hinsch filed Form 4/A - Amendment for ProQR Therapeutics N.V. (PRQR) on 30 Jun 2026.

Key facts

This page summarizes Gylvin Lykke Hinsch's Form 4/A - Amendment filing for ProQR Therapeutics N.V. (PRQR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jun 2026, 16:02.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0002135139 Primary reporting owner

Hinsch Gylvin Lykke

Relationship: Director
Address: PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, LEIDEN, NETHERLANDS
Signature: /s/ Pieter Erik de Ridders, Attorney-in-Fact
Signature date: 30 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRQR transaction Derivative

Share Option (Right to Buy)

Award

Transaction value
Shares: +14,595
Change %
Price: $0.000000^*
Shares after: 14,595
Date: 02 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 14,595
Exercise price: $1.42
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.

Footnote F2

25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC remarks

This Form 4/A amends the Form 4 filed on June 3, 2026 solely to correct the number of share options reported. No other information in the original Form 4 has been changed.